Seelos Therapeutics – Consensus Indicates Potential 352.0% Upside

Broker Ratings

Seelos Therapeutics found using ticker (SEEL) now have 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 12 and 4 and has a mean target at 8. With the stocks previous close at 1.77 this is indicating there is a potential upside of 352.0%. There is a 50 day moving average of 1.02 while the 200 day moving average is 0.98. The company has a market cap of $96m. Find out more information at:

Seelos Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics was founded in 2016 and is headquartered in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index